The CXCL10/CXCR3 pathway has been found to show impact on the resistance to EGFR-tyrosine kinase inhibitors which was demonstrated by cytokine array analysis during in vitro coculture with tumor cells and activated PBMCs treated with EGFR-TKI 25. This evidence concerns the gene CXCR3 and neoplasm.